Oral Cannabidiol for Opioid Withdrawal

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal. The study will be a residential within-subject comparison; all participants will receive placebo dosing and active cannabidiol. Results may be used to support an R01 grant application to more closely examine this hypothesis.
Epistemonikos ID: b4b923b8ffecb2c43781bc176daa89948f5505c0
First added on: May 07, 2024